Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Offers Possible Reasons For Vectibix Failure To Show Survival Benefit

Executive Summary

FDA review documents for Amgen's Vectibix (panitumumab) outline possible factors that may have lead to the epidermal growth factor receptor inhibitor's failure to show an overall survival benefit in a pivotal trial, including the possibility that the trial was not powered to show a modest effect

You may also be interested in...



Accelerated “De-proval”? FDA May Be Ready To Withdraw Subpart H Drug

FDA is moving towards potentially withdrawing, for the first time, a drug brought to market under the Subpart H accelerated approval mechanism

Accelerated “De-proval”? FDA May Be Ready To Withdraw Subpart H Drug

FDA is moving towards potentially withdrawing, for the first time, a drug brought to market under the Subpart H accelerated approval mechanism

FDA Waiting For EGFR Diagnostic Kit Data As Supplement To Vectibix BLA

In what could signal a trend for targeted therapies, FDA concluded in its review of Amgen's epidermal growth factor receptor inhibitor Vectibix that the diagnostic test kit used to screen subjects for EGFR expression would need to be submitted as a supplement to the BLA

Latest News
See All
UsernamePublicRestriction

Register

PS048199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel